MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies Book Value 2011-2026 | BHC
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -82 M | 260 M | -34 M | 605 M | 1.14 B | 2.82 B | 5.94 B | 3.26 B | 6.03 B | 5.43 B | 5.23 B | 3.72 B | 4.01 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.03 B | -82 M | 2.95 B |
Quarterly Book Value Bausch Health Companies
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -227 M | -174 M | -82 M | -235 M | 271 M | 145 M | 260 M | 433 M | 253 M | -141 M | -34 M | -135 M | -611 M | -34 M | 605 M | 605 M | 605 M | 605 M | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 2.82 B | 2.82 B | 2.82 B | 2.82 B | 5.94 B | 5.94 B | 5.94 B | 5.94 B | 3.26 B | 3.26 B | 3.26 B | 3.26 B | 6.03 B | 6.03 B | 6.03 B | 6.03 B | 5.4 B | 5.43 B | 5.43 B | 5.43 B | 5.2 B | 5.23 B | 5.23 B | 5.23 B | 3.72 B | 3.72 B | 3.72 B | 3.72 B | 3.93 B | 4.01 B | 4.01 B | 4.01 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.03 B | -611 M | 2.82 B |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
Aurora Cannabis
ACB
|
609 M | $ 3.34 | 0.76 % | $ 86.3 M |  Canada |
 |
China Pharma Holdings
CPHI
|
7.75 M | $ 0.63 | 1.12 % | $ 11 M |  China |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
Pacira BioSciences
PCRX
|
778 M | $ 22.99 | 1.5 % | $ 1.06 B | USA |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
1.71 B | $ 2.58 | 2.38 % | $ 1.34 B | Canada |
 |
Perrigo Company plc
PRGO
|
2.94 B | $ 9.71 | 1.41 % | $ 1.34 B | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
649 M | $ 8.04 | -0.12 % | $ 412 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Rockwell Medical
RMTI
|
21.3 M | $ 1.03 | 1.47 % | $ 24 M | USA |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 0.88 | 0.48 % | $ 43.9 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 3.18 | 4.26 % | $ 44.7 M | USA |
 |
Solid Biosciences
SLDB
|
180 M | $ 6.76 | -5.32 % | $ 592 M | USA |
 |
Sundial Growers
SNDL
|
1.1 B | $ 1.38 | 1.1 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 2.34 | -8.24 % | $ 2.9 M | USA |
 |
Harrow Health
HROW
|
52.1 M | $ 35.29 | 3.79 % | $ 1.3 B | USA |
 |
Tilray
TLRY
|
3.33 B | $ 6.7 | 3.8 % | $ 4.14 B | Canada |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
-23.1 M | $ 4.49 | -4.17 % | $ 289 M | USA |
 |
Veru
VERU
|
32.3 M | $ 2.32 | 0.9 % | $ 313 M | USA |
 |
Viatris
VTRS
|
21.1 B | $ 13.43 | 1.02 % | $ 16.1 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Relmada Therapeutics
RLMD
|
86.5 M | $ 6.06 | 3.33 % | $ 239 M | USA |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.36 | -0.15 % | $ 402 M | Canada |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | USA |
 |
TherapeuticsMD
TXMD
|
29.3 M | $ 2.32 | 0.22 % | $ 24.2 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
cbdMD
YCBD
|
1.96 M | $ 0.79 | 4.11 % | $ 3.41 M | USA |
 |
Organogenesis Holdings
ORGO
|
385 M | $ 2.44 | -1.42 % | $ 321 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | Canada |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 0.96 | -0.86 % | $ 103 M | Canada |
 |
Assertio Holdings
ASRT
|
94 M | $ 16.16 | 15.43 % | $ 103 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |